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z Evidence summary
Diabetes mellitus and osteoarthritis com-
monly overlap in patients, many of whom
have looked to the nutritional supplement
combination of glucosamine and chon-
droitin sulfates for pain relief. The effec-
tiveness of these supplements in improving
patient-oriented outcomes for osteoarthri-
tis is still being evaluated. However,
regardless of their effectiveness they
remain popular supplements, representing
up to a third of the specialized supplement
Despite theoretical risks based on animal
models given high intravenous doses,
glucosamine/chondroitin (1500 mg/1200 mg
daily) does not adversely affect short-term
glycemic control for patients whose dia-
betes is well-controlled, or for those without
diabetes or glucose intolerance (SOR: A,
consistent, good-quality patient-oriented
evidence). Some preliminary evidence sug-
gests that glucosamine may worsen glu-
cose intolerance for patients with untreated
or undiagnosed glucose intolerance or 
diabetes (SOR: C, extrapolation from 
disease-oriented evidence).
Long-term effects are unknown; 
however, no compelling theoretical or 
incidental data suggest that long-term
results should be different (SOR: C,
expert opinion). Further studies are
required to clarify the effects of 
glucosamine on patients with poorly 
controlled diabetes or glucose intolerance.
E V I D E N C E - B A S E D A N SW E R
These products seem to be 
a safe alternative to NSAIDs
Glucosamine/chondroitin is a popular 
over-the-counter supplement used by many
patients; it appears to be without any 
serious adverse affects or drug interactions.
It does not seem to have much effect on
blood sugar for patients with diabetes. It
may relieve symptoms for some patients
with pain due to osteoarthritis. As such,
glucosamine/chondroitin seems to be a
safe alternative to nonsteroidal anti-
inflammatory drugs (NSAIDs) for patients
with osteoarthritis.
I would monitor blood sugars more 
frequently for patients with diabetes given
the low numbers in the studies cited above.
I would avoid glucosamine/chondroitin 
during pregnancy and lactation for the
younger symptomatic female patient. The
cost of this product varies widely, and this
can be a factor for patients since they are
paying out of pocket.
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University of Wyoming, Cheyenne
C L I N I C A L C OMMEN TA R Y
Peter D. Marshall, MD,
Sourav Poddar, MD 
Department of Family
Medicine, University of
Colorado Health Sciences
Center, Denver
Elizabeth M. Tweed, MLIS
University of Colorado Health
Sciences Center, Denver
VOL 55, NO 12 / DECEMBER  2006 1091w w w. j f p o n l i n e . c o m
Copy
right
® Dow
den H
ealth
 Med
ia  
For p
erson
al us
e onl
y
For mass reproduction, content licensing and permissions contact Dowden Health Media.
market in the US.1
The mechanism by which glucosamine
is hypothesized to affect blood glucose
involves the roles of glucosamine and the
hexosamine biosynthesis pathway in 
the regulation of glucose transport.
Overexpression of enzymes involved in
this pathway have led to high levels of glu-
cose and insulin resistance in animals given
huge doses of intravenous glucosamine
(100–200 times higher than oral therapeu-
tic doses in humans).2 Studies have specifi-
cally investigated the effects of intravenous
glucosamine infusion in healthy humans,
and it did not show any effect on insulin
sensitivity or plasma glucose.
A Cochrane systematic review of 20
randomized controlled trials (RCTs)
including 2570 patients in order to evalu-
ate the effectiveness and toxicity of glu-
cosamine in osteoarthritis found that 
glucosamine was as safe as placebo in
terms of adverse reactions. However, they
did not comment specifically on diabetic
patients or hyperglycemia per se.3
An RCT published in 2004 tested
whether glucose intolerance occurs when
healthy adults consume normal, recom-
mended dosages of glucosamine sulfate.
Nineteen healthy adults were randomized
to receive either 1500 mg of glucosamine
sulfate or placebo orally each day for 12
weeks. Three-hour oral glucose tolerance
tests were performed using 75 g of dex-
trose. These occurred before the study, at 6
weeks, and at 12 weeks. There were no sig-
nificant differences between fasting levels
of serum insulin or blood glucose.4
Glucosamine sulfate supplementation did
not alter serum insulin or plasma glucose
during the tests. Limitations to the study
include the small number of subjects, the
short duration period, and the fact that the
tests were performed before the patient’s
daily glucosamine dosing.
A recent study examined insulin and
glucose levels with and without the simul-
taneous ingestion of 1500 mg of glu-
cosamine. Sixteen fasting volunteers with
osteoarthritis but without known diabetes
or glucose intolerance received 7 g of glu-
cose with or without ingestion of 1500 mg
glucosamine sulfate. The authors unex-
pectedly uncovered undiagnosed diabetes
or impaired glucose tolerance in 3 subjects.
These 3 subjects showed a statistically sig-
nificant (P=.04) 31% increase in the area
under the curve of glucose levels following
the test. There was no effect of glu-
cosamine sulfate ingestion on patients with
normal baseline glucose testing or on
insulin levels. Their results might be
important since they are the first to suggest
that glucosamine ingestion may affect glu-
cose levels in individuals who have
untreated diabetes or glucose intolerance.5
One double-blinded RCT evaluated
whether oral glucosamine supplementa-
tion altered glycosylated hemoglobin
(HbA1c) concentrations for patients with
well-controlled diabetes mellitus. Thirty-
eight patients were randomized to receive
either treatment with glucosamine/chon-
droitin at the recommended doses or
placebo. After 3 months of treatment
HbA1c levels did not change and were not
significantly different between groups
(P=.2).6
Another study addressed whether glu-
cosamine taken at recommended doses for
the treatment of osteoarthritis had any
detrimental effect on glucose metabolism.
Fourteen patients participated and had a
baseline 4-hour meal tolerance test and 
a frequently sampled intravenous glucose
tolerance test, before and after 4 weeks of
glucosamine sulfate treatment (500 mg
orally 3 times daily). After 4 weeks they
found no change in fasting plasma glucose,
insulin, glucose tolerance, or difference in
insulin sensitivity in the group of subjects.7
Again, the study was limited by a small
subject number and short duration of
study. 
Recommendations from others
The PDR for Nonprescription Drugs and
Dietary Supplements states that “glu-
cosamine is likely safe for patients with
diabetes that is well controlled with diet
only or with one or two oral antidiabetic
agents (HbA1c less than 6.5%). For
Glucosamine and
chondroitin do not
have much effect
on blood sugar,
and may relieve
the pain 
of osteoarthritis 
for some patients 
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patients with higher HbA1c concentrations
or for those requiring insulin, closely mon-
itor blood glucose concentrations.”8
The American Pain Society encourages
adults with osteoarthritis to take 1500 mg
of glucosamine daily as a dietary supple-
ment but does not specifically recommend
it as pharmacologic management for pain.9
The American College of Rheumatology
Subcommittee on Osteoarthritis has no
recommendations regarding the use of glu-
cosamine or chondroitin in the treatment
of knee osteoarthritis.10
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